MA47215A - Procédés prédictifs et diagnostiques pour le cancer de la prostate - Google Patents
Procédés prédictifs et diagnostiques pour le cancer de la prostateInfo
- Publication number
- MA47215A MA47215A MA047215A MA47215A MA47215A MA 47215 A MA47215 A MA 47215A MA 047215 A MA047215 A MA 047215A MA 47215 A MA47215 A MA 47215A MA 47215 A MA47215 A MA 47215A
- Authority
- MA
- Morocco
- Prior art keywords
- predictive
- prostate cancer
- diagnostic procedures
- diagnostic
- procedures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443831P | 2017-01-09 | 2017-01-09 | |
| US201762473507P | 2017-03-20 | 2017-03-20 | |
| US201762561218P | 2017-09-21 | 2017-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47215A true MA47215A (fr) | 2019-11-13 |
Family
ID=62791142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047215A MA47215A (fr) | 2017-01-09 | 2018-01-09 | Procédés prédictifs et diagnostiques pour le cancer de la prostate |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11613785B2 (fr) |
| EP (1) | EP3565560A4 (fr) |
| MA (1) | MA47215A (fr) |
| WO (1) | WO2018129497A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3322448A4 (fr) | 2015-07-16 | 2019-03-06 | Bioxcel Therapeutics, Inc. | Nouvelle approche pour le traitement du cancer par immunomodulation |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
| WO2020123477A1 (fr) * | 2018-12-10 | 2020-06-18 | Bioxcel Therapeutics, Inc. | Traitements combinés pour traiter des maladies à l'aide d'un agent modifiant l'immunité innée et d'un agoniste de l'ox40 |
| US20220089733A1 (en) * | 2018-12-10 | 2022-03-24 | Bioxcel Therapeutics, Inc. | Novel approach for treatment of cancer using immunomodulation |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
| DE60029230T2 (de) | 1999-09-10 | 2007-06-06 | The University Of Sydney, Sydney | Dipeptidyl-peptidasen |
| WO2001068708A2 (fr) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a) |
| GB0027552D0 (en) | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
| AU2006246719A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| KR20080030079A (ko) | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
| EP1760076A1 (fr) | 2005-09-02 | 2007-03-07 | Ferring B.V. | Inhibiteur de FAP |
| EP1806365A1 (fr) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| RU2011116223A (ru) | 2008-09-25 | 2012-10-27 | Моликьюлар Инсайт Фармасьютикалз, Инк. (Us) | Селективные ингибиторы сепразы |
| SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
| EP2389176A4 (fr) | 2009-01-23 | 2012-08-01 | Univ Sydney | Nouvelle thérapie pour maladie métabolique |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| CN102574921B (zh) | 2009-09-29 | 2016-05-04 | 罗切格利卡特公司 | 双特异性死亡受体激动型抗体 |
| CA2776037A1 (fr) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anticorps diriges contre la proteine d'activation du fibroblaste, et utilisations et procedes correspondants |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| US20140088019A1 (en) | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| EP2753334B1 (fr) | 2011-08-30 | 2022-10-19 | Trustees Of Tufts College | Inhibiteurs de protéasome activés par fap utilisés pour traiter les tumeurs solides |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013107820A1 (fr) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Nouveaux inhibiteurs de fap |
| WO2014055442A2 (fr) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions et procédés de ciblage de cellules stromales pour le traitement du cancer |
| WO2014068023A1 (fr) | 2012-11-02 | 2014-05-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Inhibiteurs peptidiques de dpp8 et dpp9 |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| PL3041827T3 (pl) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
| PL3041828T3 (pl) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Technologies Limited | Pochodne 1,3,4-oksadiazolu i 1,3,4-tiadiazolu jako immunomodulatory |
| EP3322448A4 (fr) * | 2015-07-16 | 2019-03-06 | Bioxcel Therapeutics, Inc. | Nouvelle approche pour le traitement du cancer par immunomodulation |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
-
2018
- 2018-01-09 US US16/476,420 patent/US11613785B2/en active Active
- 2018-01-09 EP EP18736583.8A patent/EP3565560A4/fr active Pending
- 2018-01-09 MA MA047215A patent/MA47215A/fr unknown
- 2018-01-09 WO PCT/US2018/012876 patent/WO2018129497A1/fr unknown
-
2023
- 2023-01-20 US US18/157,717 patent/US20230227918A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3565560A4 (fr) | 2021-01-13 |
| US20210355541A1 (en) | 2021-11-18 |
| EP3565560A1 (fr) | 2019-11-13 |
| WO2018129497A1 (fr) | 2018-07-12 |
| US11613785B2 (en) | 2023-03-28 |
| US20230227918A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
| IL274246A (en) | Methods for diagnosing and treating cancer | |
| MA42238A (fr) | Procédés de diagnostic du cancer de la vessie | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
| MA47215A (fr) | Procédés prédictifs et diagnostiques pour le cancer de la prostate | |
| IL273071A (en) | Treatment and diagnosis methods for cancer | |
| IL258378A (en) | Prostate-specific membrane antigen inhibitors are labeled with 18f and used as imaging agents for prostate cancer. | |
| MA46927A (fr) | Procédés de détection du cancer | |
| ZA202000851B (en) | Antibodies useful in cancer diagnosis | |
| HK1243434A1 (zh) | Igf-1r抗體及其診斷癌症的用途 | |
| GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
| DK3526347T3 (da) | Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer | |
| IL280421A (en) | Cancer treatment by antibody | |
| ITUA20161418A1 (it) | Biomarcatori urinari per la diagnosi del carcinoma della prostata | |
| GB201917428D0 (en) | Prostate cancer diagnostic | |
| HK1248730A1 (zh) | Igf-1r抗體及其用於癌症診斷的用途 | |
| GB201813138D0 (en) | Cancer treatment with an antibody | |
| PT3643707T (pt) | Composto marcado com 18f para o diagnóstico do cancro da próstata e a respetiva utilização | |
| GB201510873D0 (en) | Diagnostic, predictive and prognostic testing for cancer |